GE HealthCare Techs (NASDAQ:GEHC) Bolsa

GE HealthCare Techs

GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (45% of revenue), advanced visualization solutions (26%), patient care solutions (16%), and pharmaceutical diagnostics (13%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 46%, 26%, 12%, and 17% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (about one third of revenue), pharmaceutical diagnostics (about 10%-15%), and digital solutions (just over 5%).

Earnings

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

COIN

FSLY

GEHC

HUBS

Wall Street anticipa importantes reportes financieros. Expectativas para Deere, Fastly, GE HealthCare y HubSpot y Coinbase.

Acciones a seguir en Wall Street hoy: Deere, Fastly, GE HealthCare y más

GE HealthCare Technologies Inc. - Common Stock

GE HealthCare Technologies Inc

LXEH

Lixiang Education Shares Resume Trading

Piper Sandler analyst Biren Amin maintains Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>) with a Overweight and lowers the price target from $182 to $110.

Price Target

Analyst Ratings

SRPT

Piper Sandler Maintains Overweight on Sarepta Therapeutics, Lowers Price Target to $110

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
RARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology&nbsp;plenary session on Saturday, April 26.
A second plenary presentation will feature first&nbsp;results from Cohort 4 of the Phase 2b SunRISe-1 study evaluating TAR-200 monotherapy in patients with BCG–unresponsive, papillary-only HR-NMIBC. In this patient population, bladder removal remains a standard treatment, but many patients are elderly, have significant comorbidities, or are unwilling to undergo radical surgery, making treatment challenging.

Johnson & Johnson Says First Results From Cohort 4 Of Phase 2B Sunrise-1 Study Show Potential Of TAR-200 Monotherapy In Patients With Papillary-only, High-risk Non-muscle Invasive Bladder Cancer

MLGO

MicroAlgo Shares Halted On Circuit Breaker To The Upside, Stock Now Up 56%

<a href="https://www.bloomberg.com/news/articles/2025-04-21/air-india-keen-to-take-boeing-planes-refused-by-chinese-airlines">https://www.bloomberg.com/news/articles/2025-04-21/air-india-keen-to-take-boeing-planes-refused-by-chinese-airlines</a>

General

'Air India Keen To Take Boeing Planes Refused By Chinese Airlines'- Bloomberg

TAR-200 monotherapy shows highest complete response with sustained benefits in 12-month data from Phase 2b SunRISe-1 study (Cohort 2)
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer
RARITAN, N.J., April 21, 2025 /PRNewswire/ -- Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced today that new data from its leading oncology pipeline will be presented at the American Urological Association (AUA) 2025 Annual Meeting, taking place April 26-29 in Las Vegas. Among the highlights are the 12-month duration of response (DOR) data from the Phase 2b Cohort 2 SunRISe-1 study, evaluating TAR-200—an intravesical gemcitabine releasing system—for patients with Bacillus Calmette-Guérin (BCG)—unresponsive, high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma in situ (CIS) with or without papillary disease. These findings will be featured in the Practice-changing, Paradigm-shifting Clinical Trials in Urology&nbsp;plenary session on Saturday, April 26.

Johnson & Johnson Says TAR-200 Monotherapy Shows Highest Complete Response With Sustained Benefits In 12-month Data From Phase 2B SunRISe-1 Study (Cohort 2)

On Monday, Nvidia Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)&nbsp;chief&nbsp;Jensen Huang&nbsp;met with Japanese Prime Minister&nbsp;Shigeru Ishiba&nbsp;to canvass more electricity to power <a target="_blank" href="https://www.benzinga.com/topic/nvidia" rel="noreferrer noopener">artificial intelligence&#8217;s needs</a>.
Huang&nbsp;and Ishiba discussed how Japan is particularly positioned well to develop AI, given its leadership in robotics and industrial manufacturing. They acknowledged the importance of electric energy generation and new infrastructure to power their AI ambitions, Bloomberg reported, <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-04-21/nvidia-ceo-lobbies-japan-for-more-power-data-centers-to-fuel-ai?srnd=phx-technology&amp;sref=TBDibEcD" rel="noreferrer noopener">citing</a> Huang.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/global/25/04/44709732/foxconn-eyes-nissan-mitsubishi-in-japan-ev-push-to-counter-chinas-growing-auto-threat" rel="noreferrer noopener">Foxconn Eyes Nissan, Mitsubishi In Japan EV Push To Counter China&#8217;s Growing Auto Threat</a>
However, Huang also said that generating and creating intelligence will need energy.
Huang visited Beijing last week. Meanwhile, U.S. President Donald Trump shared plans to prohibit Nvidia from selling H20 AI chip to China amid intensifying geopolitical tensions spurred by U.S. blacklisting of Chinese companies like Huawei Technologies, semiconductor sanctions restricting China&#8217;s access to advanced semiconductor technologies, and a tariff war between the countries.
Last week, Nvidia warned of a $5.5 billion&nbsp;writedown&nbsp;from the newest U.S. chip embargo.
Redburn Atlantic analyst&nbsp;Timm Schulze-Melander&nbsp;<a target="_blank" href="https://www.benzinga.com/government/regulations/25/04/44846329/nvidias-china-sales-face-setback-as-h20-chip-restrictions-catch-key-buyers-off-guard-reuters" rel="noreferrer noopener">named Nvidia a</a> &#8216;top pick,&#8217; citing investments in leading-edge AI and chipmaking.
<a target="_blank" href="https://www.benzinga.com/25/04/44631510/asml-to-boost-japan-workforce-5x-amid-global-race-for-advanced-semiconductor-tech" rel="noreferrer noopener">Recent reports indicated</a> Dutch advanced chipmaking equipment supplier&nbsp;ASML Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>)&nbsp;plans to quintuple its Japan-based maintenance staff for the machines. Japan continues bolstering its advanced semiconductor technology position, as in the U.S., Europe, and China.
Japanese multinational investment holding company&nbsp;Softbank Group Corp (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBF#OTC">SFTBF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SFTBY#OTC">SFTBY</a>) is&nbsp;also weighing a loan&nbsp;of up to $16.5 billion to finance its&nbsp;U.S. AI ambitions.
Price Action: NVDA stock is down 3.32% at $98.12 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/downgrades/25/04/44875404/amkor-stock-under-pressure-analyst-cuts-rating-due-to-trade-policy-concerns-slowing-end-market-growth" target="_blank" rel="noreferrer noopener">Amkor Stock Under Pressure: Analyst Cuts Rating Due To Trade Policy Concerns, Slowing End Market Growth</a></li>
</ul>
Photo by glen photo via Shutterstock

Government

Regulations

Tech

Media

ASML

NVDA

SFTBF

SFTBY

Nvidia's Jensen Huang Meets Japanese PM To Discuss AI's Growing Energy Needs

Piper Sandler analyst Kashy Harrison maintains Fluence Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLNC#NASDAQ">FLNC</a>) with a Neutral and lowers the price target from $10 to $4.

FLNC

Piper Sandler Maintains Neutral on Fluence Energy, Lowers Price Target to $4

Lixiang Education Shares Halted On Circuit Breaker To The Downside, Stock Now Down -72.7%

Piper Sandler analyst Kashy Harrison maintains First Solar (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>) with a Overweight and lowers the price target from $230 to $205.

FSLR

Piper Sandler Maintains Overweight on First Solar, Lowers Price Target to $205

Fast-food chain Chipotle Mexican Grill Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CMG#NYSE">CMG</a>) announced Monday that it is preparing its <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/n44894998/chipotle-signs-development-agreement-with-alsea-to-open-restaurants-in-mexico-for-the-first-time" rel="noreferrer noopener">first foray into the Mexican market</a> through a newly signed partnership with Latin American restaurant operator Alsea.
The move is expected to result in the opening of Chipotle&#8217;s inaugural restaurant in Mexico by early 2026, signaling a major step in the fast-casual chain&#8217;s international expansion.
Alsea, which operates major dining brands across Latin America and Europe, will collaborate with Chipotle on launching the brand.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44876406/retail-slowdown-and-tariff-turbulence-hit-leisure-stocks-says-analyst" rel="noreferrer noopener">Retail Slowdown, Tariffs Jolt Leisure Stocks: Analyst Revises Estimates For Topgolf, Harley-Davidson And More</a>
Following this initial opening, the two companies plan to assess further growth potential in additional Latin American markets.
&#8220;We are confident that our responsibly sourced, classically-cooked real food will resonate with guests in&nbsp;Mexico,&#8221; said&nbsp;Chief Business Development Officer at Chipotle, Nate Lawton.
&#8220;The country&#8217;s familiarity with our ingredients and affinity for fresh food make it an attractive growth market for our company.&#8221;
Chipotle&#8217;s first international development agreement was made in 2023, with Alshaya Group, which has since brought five Chipotle locations to the Middle East, three in Kuwait and two in the UAE.
Globally, Chipotle already operates more than 3,700 outlets, including dozens of sites in Canada, the UK, France, and Germany.
The company aims to launch between 315 and 345 new restaurants in 2025 alone. Its long-term vision includes establishing up to 7,000 locations across the U.S. and Canada.
Chipotle reported a <a target="_blank" href="https://www.benzinga.com/general/restaurants/25/02/43479897/chipotle-q4-earnings-revenue-miss-eps-beat-focus-on-generous-portions-drives-food-costs-higher-shares-slide" rel="noreferrer noopener">13.1% increase in its fourth-quarter </a>revenue to $2.845 billion. The company expects full-year 2025 comparable restaurant sales growth in the low- to mid-single-digit range.&nbsp;
Price Action: CMG shares traded lower by 1.43% at $47.48 at the last check on Monday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/04/44867319/chip-maker-micron-splits-into-four-business-units-to-accelerate-ai-strategy" target="_blank" rel="noreferrer noopener">Chip Maker Micron Splits Into Four Business Units To Accelerate AI Strategy</a></li>
</ul>
Photo by Northfoto via Shutterstock

Chipotle To Open First Mexico Restaurant By 2026

Piper Sandler analyst Andrew Liesch maintains Great Southern Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSBC#NASDAQ">GSBC</a>) with a Neutral and lowers the price target from $62 to $58.

GSBC

Piper Sandler Maintains Neutral on Great Southern Bancorp, Lowers Price Target to $58

<a href="https://www.supremecourt.gov/orders/ordersofthecourt" title="https://www.supremecourt.gov/orders/ordersofthecourt">https://www.supremecourt.gov/orders/ordersofthecourt</a>

Politics

SWBI

Supreme Court Declines To Hear Minnesota's Appeal Defending State's Age Minimum Of 21 To Carry Handguns In Public

Piper Sandler analyst Mark Fitzgibbon maintains Independent Bank (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDB#NASDAQ">INDB</a>) with a Neutral and lowers the price target from $74 to $63.

INDB

Piper Sandler Maintains Neutral on Independent Bank, Lowers Price Target to $63

BWS Financial analyst Hamed Khorsand maintains Movado Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOV#NYSE">MOV</a>) with a Buy and maintains $31.5 price target.

BWS Financial Maintains Buy on Movado Group, Maintains $31.5 Price Target

WIIM

CING

Cingulate shares are trading lower after Ascendiant Capital cut its price target on the stock from $75 to $60.

D. Boral Capital analyst Jason Kolbert maintains Enlivex Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENLV#NASDAQ">ENLV</a>) with a Buy and maintains $13 price target.

ENLV

D. Boral Capital Maintains Buy on Enlivex Therapeutics, Maintains $13 Price Target

Initial deal valued at approximately $1.4 million
Cashflow on Wheels is a leading logistics company with a focus on transitioning FedEx and Amazon last-mile local delivery to electric vehicles
BREA, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- via IBN -- <a href="https://www.globenewswire.com/Tracker?data=u4fZzmgfNquA6PJZLhoovkh88mre5m_RKlQvpOQica1lxofB3se4d7qeQ3EOkaUTd-udoILOBUxN9saVqLsoZ2xiKNFh98s-RvhldYZmaBM=">Mullen Automotive, Inc.</a> (NASDAQ:<a href="https://www.globenewswire.com/Tracker?data=-jGbHtC9iyBKx1CrZHAC8OTnYPRD8MI25AlY_mg0ajaWkF9_RLMzHbUo086RGzmh5DirKMMkEz9CcnnTbHKUXVqJ3M_s1JFF1sEyxdGWylJe7Vl3_8awoY2i_Q7Foqm5"> MULN</a>) ("Mullen" or the "Company"), an electric vehicle ("EV") manufacturer, announces today a Class 3 vehicle order with Cashflow on Wheels. The order includes 20 all electric Mullen THREE's, with a retail value of approximately $1.4 million. Cashflow on Wheels is a leading logistics company based in Houston, Texas, with a focus on last-mile delivery, local and long-distance trucking and transportation solutions. The milestone vehicle order will be fulfilled by Mullen dealer, Pritchard Automotive.&nbsp;
Cashflow on Wheels' strength is in bringing new efficiencies and sustainability to last-mile delivery for FedEx and Amazon. The addition of the Mullen THREE to their fleet underscores a commitment to transitioning traditional fleets to advanced EV solutions and to their DSPs reducing their total cost of operations.&nbsp;&nbsp;

MULN

Mullen Automotive Announces Class 3 Vehicle Order With Cashflow On Wheels; Order Includes 20 All Electric Mullen THREE's, With Retail Value Of About $1.4M

SBFM

Sunshine Biopharma shares are trading higher after the company announced the launch of its oncology drug Everolimus in Canada.

Needham analyst Laura Martin reiterates Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Buy and maintains $14 price target.

Reiteration

MGNI

Needham Reiterates Buy on Magnite, Maintains $14 Price Target

Press Releases

GE HealthCare and NVIDIA reimagine diagnostic imaging with autonomous X-ray and ultrasound solutions

GE HealthCare launches AI-driven, patient-friendly Invenia ABUS Premium to accelerate scanning and drive early cancer detection in dense breasts

ACC 2025: GE HealthCare announces the U.S. launch of pivotal innovations that will help transform the cardiology care pathway

GE HealthCare announces cash dividend for first quarter of 2025

GE HealthCare unveils Revolution™ Vibe CT system with Unlimited One-Beat Cardiac imaging and AI Solutions

GE HealthCare Completes Acquisition of Nihon Medi-Physics (NMP), a Leading Radiopharmaceutical Company in Japan

Small Cap

Opinion

FDA Watch: The Quiet Gold Rush in AI-Powered Medical Devices

GE HealthCare names Jeannette Bankes president and CEO, Patient Care Solutions

Cincinnati Children's and GE HealthCare build collaborative research program to drive pediatric imaging innovation

Comments

GE HealthCare Techs

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL